Indian Firms Must Be In Indian Hands, Says Government Paper; Highlights Threats to Compulsory Licensing And Drug Pricing
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Ambitions of leading multinational companies for a long-term positioning in India through acquisition of generic companies may face rigid policy restrictions from a government concerned about monopoly-dictated pricing for needed drugs
You may also be interested in...
India Maintains Status Quo On Compulsory Licensing Provisions
Indian generics industry, multi-national company lobbies welcome moves to keep flexibility, but doubts linger regarding future investments.
India Maintains Status Quo On Compulsory Licensing Provisions
Indian generics industry, multi-national company lobbies welcome moves to keep flexibility, but doubts linger regarding future investments.
India Maintains Status Quo On Compulsory Licensing Provisions; Indian, MNC Lobbies Welcome Moves To Keep Flexibility But Future Doubts Linger
MUMBAI - Lobby groups from both the Indian generics industry and multinational companies hailed a decision by the Indian government to maintain the status quo on legal provisions that determine the conditions needed to trigger a compulsory license for a drug. But both sides expressed apprehension on how the present set of norms will unfold, fearing that future investments or market opportunities may be at risk if wrong moves are made